Subscribe Us

header ads

Recents

header ads

Antifungal Drugs Market Size At Around US$ 22.88 Bn In 2032

The antifungal drugs market would grow at a CAGR of 3.49% over the predicted time frame. The market is expected to increase in value from US$ 16.24 Bn in 2022 to US$ 22.88 Bn in 2032.

Antifungal Drugs Market Size 2023 To 2032

The on antifungal drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2600

A recent report provides crucial insights along with application based and forecast information in the Global Antifungal drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Antifungal drugs market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Antifungal drugs market are included as given below:

Antifungal drugs Market Key Players

  • Pfizer, Inc.
  • Novartis AG
  • Sanofi
  • GlaxoSmithKline plc
  • Bayer AG
  • Glenmark
  • Abbott
  • AstellasPharma, Inc.
  • Enzon Pharmaceuticals, Inc.

Market Segments

By Drug Class

  • Echinocandins
  • Azoles
  • Allylamines
  • Polyenes
  • Others

By Indication

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Others

By Infection Type

  • Systemic Antifungal Infections
  • Superficial Antifungal Infections

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Report Objectives

  • To define, describe, and forecast the global antifungal drugs market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the antifungal drugs market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antifungal Drugs Market 

5.1. COVID-19 Landscape: Antifungal Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antifungal Drugs Market, By Drug Class

8.1. Antifungal Drugs Market, by Drug Class, 2023-2032

8.1.1 Echinocandins

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Azoles

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Allylamines

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Polyenes

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Antifungal Drugs Market, By Indication

9.1. Antifungal Drugs Market, by Indication, 2023-2032

9.1.1. Aspergillosis          

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Dermatophytosis

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Candidiasis

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Antifungal Drugs Market, By Infection Type 

10.1. Antifungal Drugs Market, by Infection Type, 2023-2032

10.1.1. Systemic Antifungal Infections

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Superficial Antifungal Infections

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Antifungal Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis AG

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Sanofi

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GlaxoSmithKline plc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Glenmark

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Abbott

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AstellasPharma, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Enzon Pharmaceuticals, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments